Last week, the U.S. Food and Drug Administration (FDA) took a significant step towards increased regulation of 503A human drug compounding pharmacies, which may cascade into additional state ...

HighlightsSigned an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant ...

Up to approximately 25,000 prescriptions per day in fulfillment capacity available under the agreement, with reach across all U.S. states Strengthens the Company's U.S. supply chain and regulatory ...

As the last year-plus has shown, regulations that seem to make sense in ordinary times can sometimes be revealed to have serious shortcomings during an emergency. In the public health sphere alone, ...

HighlightsSigned an agreement with a U.S.-based prescription telehealth and infrastructure partner to support compliant prescribing, fulfillment, and delivery of the Company's peptide productsBuilds ...

Peptide interest is exploding online, but the FDA's actual 2026 docket is far smaller than what's actually been reported.

Analysts and investors have turned their attention to a key regulatory meeting on peptides, a decision expected to trigger ...

Among the local drug compounding regulators for 50 states, Washington, DC, Guam, Puerto and the US Virgin Islands, many say they are working with and appreciate the help of the US Food and Drug ...

Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch product strategy and PatchPrint manufacturing platform, strengthening its position in ...

Vancouver, British Columbia--(Newsfile Corp. - June 2, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced ...